Switching to aripiprazole as a strategy for weight reduction: a meta-analysis in patients suffering from schizophrenia (Q34143822)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20871835%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

Switching to aripiprazole as a strategy for weight reduction: a meta-analysis in patients suffering from schizophrenia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20871835%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20871835%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Dov Aizenberg

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20871835%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

publication date

25 August 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20871835%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20871835%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20871835%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

3S-5S

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20871835%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 3.0 Unported

14 February 2020

copyright license

start time

1 January 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: One-year follow-up study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943136

The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943136

Aripiprazole versus other atypical antipsychotics for schizophrenia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943136

A systematic review of quality of life and weight gain-related issues in patients treated for severe and persistent mental disorders: focus on aripiprazole

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943136

A review of the safety and tolerability of aripiprazole

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943136

A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943136

A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943136

Pharmacological management of atypical antipsychotic-induced weight gain.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943136

Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943136

Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943136

Interventions to reduce weight gain in schizophrenia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943136

Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943136

The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943136

The risks and benefits of switching antipsychotics: a case study approach

5 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F898013

Naturalistic impact of second-generation antipsychotics on weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F898013

Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F898013

A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F898013

Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F898013

Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F898013

Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F898013

A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA)

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F898013

A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F898013

Amantadine for weight gain associated with olanzapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F898013

A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943136

Reversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: A case report.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943136

Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943136

Efficacy with high-dose aripiprazole after olanzapine-related metabolic disturbances

28 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20871835

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Metabolic findings from the CATIE trial and their relation to tolerability

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20871835

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1155/2011/898013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20871835%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20871835%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference